Secukinumab (AIN-457) for the treatment of Psoriasis.

Journal Article (Journal Article;Review)

Secukinumab (also known as AIN-457) is a human monoclonal antibody targeting IL-17A, which has been recently FDA-approved for the treatment of moderate to severe psoriasis and psoriatic arthritis with coexistent moderate to severe plaque psoriasis based on clinical trials demonstrating excellent efficacy. This review will address the rationale for targeting the IL-23/Th17/IL-17 axis, the role of IL-17 and Th17 cells in psoriasis and other chronic inflammatory diseases, and will examine pre-clinical studies, pharmacologic properties, clinical efficacy, and the safety profile of secukinumab.

Full Text

Duke Authors

Cited Authors

  • Jaleel, T; Elmets, C; Weinkle, A; Kassira, S; Elewski, B

Published Date

  • 2016

Published In

Volume / Issue

  • 9 / 2

Start / End Page

  • 187 - 202

PubMed ID

  • 26647300

Electronic International Standard Serial Number (EISSN)

  • 1751-2441

Digital Object Identifier (DOI)

  • 10.1586/17512433.2016.1129894


  • eng

Conference Location

  • England